Therapy of heavy metal poisoning using agents which sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound which can be eliminated from the body.
Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
Pyridine derivatives with one or more keto groups on the ring.
'Lead poisoning' is a type of heavy metal toxicity caused by increased levels of lead in the body, typically resulting from exposure to lead-containing substances or environments, and potentially leading to neurological issues, anemia, and developmental delays, especially in children.
A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.
Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.
A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.
A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.19, symbol Pb. (Dorland, 28th)
Triazoles are a class of antifungal drugs that contain a triazole ring in their chemical structure and work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting the integrity and function of the membrane.
A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.
Mercury poisoning, also known as hydrargyria, is a type of metal toxicity caused by exposure to excessive levels of mercury, leading to harmful effects on the nervous system, kidneys, and other organs, often resulting from improper handling or ingestion of mercury-containing substances.
Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin.
A granulomatous disease caused by the aquatic organism PYTHIUM insidiosum and occurring primarily in horses, cattle, dogs, cats, fishes, and rarely in humans. It is classified into three forms: ocular, cutaneous, and arterial.
An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.
Neurologic conditions in adults associated with acute or chronic exposure to lead or any of its salts. The most common lead related neurologic syndrome in adults consists of a polyneuropathy involving motor fibers. This tends to affect distal nerves and may present as wrist drop due to RADIAL NEUROPATHY. Additional features of chronic lead exposure include ANEMIA; CONSTIPATION; colicky abdominal pain; a bluish lead line of the gums; interstitial nephritis (NEPHRITIS, INTERSTITIAL); and saturnine gout. An encephalopathy may rarely occur. (From Adams et al., Principles of Neurology, 6th ed, p1212)
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Therapeutic practices which are not currently considered an integral part of conventional allopathic medical practice. They may lack biomedical explanations but as they become better researched some (PHYSICAL THERAPY MODALITIES; DIET; ACUPUNCTURE) become widely accepted whereas others (humors, radium therapy) quietly fade away, yet are important historical footnotes. Therapies are termed as Complementary when used in addition to conventional treatments and as Alternative when used instead of conventional treatment.
A province of western Canada, lying between the provinces of British Columbia and Saskatchewan. Its capital is Edmonton. It was named in honor of Princess Louise Caroline Alberta, the fourth daughter of Queen Victoria. (From Webster's New Geographical Dictionary, 1988, p26 & Room, Brewer's Dictionary of Names, 1992, p12)
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. (1/159)

The tumor-associated glycoprotein 72 (TAG-72) antigen is present on a high percentage of tumor types including ovarian carcinomas. Antibody B72.3 is a murine monoclonal recognizing the surface domain of the TAG-72 antigen and has been widely used in human clinical trials. After our initial encouraging studies (M. G. Rosenblum et al., J. Natl. Cancer Inst., 83: 1629-1636, 1991) of tissue disposition, metabolism, and pharmacokinetics in 9 patients with ovarian cancer, we designed an escalating dose, multi-arm Phase I study of 90Y-labeled B72.3 i.p. administration. In the first arm of the study, patients (3 pts/dose level) received an i.p. infusion of either 2 or 10 mg of B72.3 labeled with either 1, 10, 15, or 25 mCi of 90Y. Pharmacokinetic studies demonstrated that concentrations of 90Y-labeled B72.3 persist in peritoneal fluid with half-lives >24 h after i.p. administration. In addition, 90Y-labeled B72.3 was absorbed rapidly into the plasma with peak levels achieved within 48 h, and levels declined slowly thereafter. Cumulative urinary excretion of the 90Y label was 10-20% of the administered dose which suggests significant whole-body retention of the radiolabel. Biopsy specimens of bone and marrow obtained at 72 h after administration demonstrated significant content of the label in bone (0.015% of the dose/g) with relatively little in marrow (0.005% of the dose/g). The maximal tolerated dose was determined to be 10 mCi because of hematological toxicity and platelet suppression. This typically occurred on the 29th day after administration and was thought to be a consequence of the irradiation of the marrow from the bony deposition of the radiolabel. In an effort to suppress the bone uptake of 90Y, patients were treated with a continuous i.v. infusion of EDTA (25 mg/kg/12 h x 6) infused immediately before i.p. administration of the radiolabeled antibody. Patients (3 pts/dose level) were treated with doses of 10, 15, 20, 25, 30, 35, 40, or 45 mCi of 90Y-labeled B72.3 for a total of 38 patients. EDTA administration resulted in significant myeloprotection, which allowed escalation to the maximal tolerated dose of 40 mCi. Dose-limiting toxicity was thrombocytopenia and neutropenia. Studies of plasma and peritoneal fluid pharmacokinetics demonstrate no changes compared with patients without EDTA pretreatment. Cumulative urinary excretion of the radiolabel was not increased in patients pretreated with EDTA compared with the untreated group. However, analysis of biopsy specimens of bone and marrow demonstrated that bone and marrow content of the 90Y label was 15-fold lower (<0.001% injected dose/g) than a companion group without EDTA. Four responses were noted in patients who received 15-30 mCi of 90Y-labeled B72.3 with response durations of 1-12 months. These results demonstrate the myeloprotective ability of EDTA, which allows safe i.p. administration of higher doses of 90Y-labeled B72.3 and, therefore, clearly warrant an expanded Phase II trial in patients with minimal residual disease after standard chemotherapy or for the palliation of refractory ascites.  (+info)

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. (2/159)

We have identified specific iron (Fe) chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class that are far more effective ligands than desferrioxamine (DFO; Richardson et al, Blood 86:4295, 1995; Richardson and Milnes, Blood 89:3025, 1997). In the present study, we have compared the effect of DFO and one of the most active chelators (2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone; 311) on molecular targets involved in proliferation. This was performed to further understand the mechanisms involved in the antitumor activity of Fe chelators. Ligand 311 was far more active than DFO at increasing Fe release from SK-N-MC neuroepithelioma and BE-2 neuroblastoma cells and preventing Fe uptake from transferrin. Like DFO, 311 increased the RNA-binding activity of the iron-regulatory proteins (IRPs). However, despite the far greater Fe chelation efficacy of 311 compared with DFO, a similar increase in IRP-RNA binding activity occurred after 2 to 4 hours of incubation with either chelator, and the binding activity was not inhibited by cycloheximide. These results suggest that, irrespective of the Fe chelation efficacy of a ligand, an increase IRP-RNA binding activity occurred via a time-dependent step that did not require protein synthesis. Further studies examined the effect of 311 and DFO on the expression of p53-transactivated genes that are crucial for cell cycle control and DNA repair, namely WAF1, GADD45, and mdm-2. Incubation of 3 different cell lines with DFO or 311 caused a pronounced concentration- and time-dependent increase in the expression of WAF1 and GADD45 mRNA, but not mdm-2 mRNA. In accordance with the distinct differences in Fe chelation efficacy and antiproliferative activity of DFO and 311, much higher concentrations of DFO (150 micromol/L) than 311 (2.5 to 5 micromol/L) were required to markedly increase GADD45 and WAF1 mRNA levels. The increase in GADD45 and WAF1 mRNA expression was seen only after 20 hours of incubation with the chelators and was reversible after removal of the ligands. In contrast to the chelators, the Fe(III) complexes of DFO and 311 had no effect on increasing GADD45 and WAF1 mRNA levels, suggesting that Fe chelation was required. Finally, the increase in GADD45 and WAF1 mRNAs appeared to occur by a p53-independent pathway in SK-N-MC and K562 cells, because these cell lines lack functional p53. Our results suggest that GADD45 and WAF1 may play important roles in the cell cycle arrest observed after exposure to these chelators.  (+info)

The influence of hemochromatosis mutations on iron overload of thalassemia major. (3/159)

BACKGROUND AND OBJECTIVE: Hemochromatosis is a genetic form of iron overload due to a defective HFE gene. Secondary iron overload is the main complication in transfusion-dependent thalassemia patients. In this work we have examined the prevalence of HFE mutations in thalassemia major and evaluated the degree of iron overload of patients with and without HFE mutations. DESIGN AND METHODS: HFE mutations were studied in 71 Italian thalassemic patients and in 189 normal controls, using PCR and restriction enzyme analysis. The degree of iron overload, assessed by serum ferritin and liver iron concentration (LIC), was compared in 17 patients with mutations in the HFE gene, and in 17 subjects with wild type HFE genotype. The two groups of patients had comparable globin gene mutations, were matched for age and were homogeneous for transfusion and chelation history. In all cases the iron balance calculated on the basis of transfusion regimen and iron excreted by chelation was available. RESULTS: The allele frequencies of C282Y and H63D were respectively 1.4% and 12.7% in patients and 1.1% and 11.4% in controls. No case of C282Y homozygosity was recorded among patients. No significant difference was found in terms of serum ferritin, LIC, or the age at chelation start between patients with and without HFE mutations. The single patient with H63D homozygosity was severely iron-loaded. INTERPRETATION AND CONCLUSIONS: Our data suggest that the presence of a single mutation in the HFE gene does not influence the severity of iron loading in thalassemia patients following a regular transfusion and chelation program.  (+info)

Beta-thalassemia and pulmonary function. (4/159)

BACKGROUND AND OBJECTIVE: The survival of patients with beta-thalassemia major and intermedia has improved considerably. This has focused attention on the long-term sequelae of the disease itself and its treatment. The effect of hemosiderosis in major organs (heart, liver, etc) are well-recognized, but the pathophysiology of any lung damage is less clearly understood. We studied lung function changes in 32 patients with beta-thalassemia. DESIGN AND METHODS: Respiratory function tests, CO diffusion and arterial blood gas analysis were performed on 19 patients with beta-thalassemia major (9 F, 10 M) and 13 with beta-thalassemia intermedia (6 M, 7 F). All investigations were performed 24 hours before the patients received a blood transfusion or when they were in a stable state hematologic condition. Echocardiography was performed in all patients and the ejection fraction was employed as a measure of cardiac function. RESULTS: No patient had clinical signs of pulmonary dysfunction. Pulmonary function tests, however, showed a reduction of all main parameters (TLC, FVC, FEV1 and RV) in most patients with beta-thalassemia major, indicating a restrictive type of dysfunction. The pulmonary function of patients with beta-thalassemia intermedia seemed to be preserved. Arterial blood gas values were within the normal range, while in some subjects CO diffusion approached the lower limits of normality. There was no evidence that the observed abnormalities in pulmonary function were secondary to congestive heart failure. INTERPRETATION AND CONCLUSIONS: Iron deposition due to repeated blood transfusions may play a central role in determining lung alterations although the majority of patients are well chelated, suggesting that more than one causal mechanisms could be involved.  (+info)

Second marrow transplants for graft failure in patients with thalassemia. (5/159)

Thirty-two thalassemic patients with a median age of 7.7 years (range 3.4-26 years) were given a second HLA-identical related marrow transplant (BMT2) for graft failure. Four patients were in class 1 and 28 patients in classes 2 and 3. Twenty-one patients had full thalassemia recurrence (first group) and 11 patients had aplastic marrows (second group) either with or without residual donor marrow cells after the first BMT (BMT1). As conditioning regimen for BMT2 all but five patients received BUCY or CY in association with total lymphoid irradiation (TLI) and/or anti-lymphocyte globulin (ALG), whereas nine patients received a new preparative regimen with hydroxyurea, azathioprine, fludarabine before conditioning with BUCY. Twenty one of 31 evaluable patients (67.7%) had initial, and 16 (51.6%) had sustained engraftment. Ten patients (32.3%) failed to engraft. Overall and event-free survival for the entire group of patients were 49% and 33%, respectively, with a median follow-up of 4 years (range 0.6-14 years) for surviving patients. Event-free survival was higher in the second group of patients compared with the first group (41% vs 29%). The second group of patients appeared to have less graft failure compared with the first group (30% vs 63%; P = 0.1). Transplant-related mortality was 28%. A linear stepwise regression analysis revealed that occurrence of graft failure within 60 days after BMT1 (P = 0.04) and absence of residual donor marrow cells (P = 0.009) predicted for graft failure following BMT2, whereas the occurrence of graft failure after 60 days (P = 0.03) had a positive influence on survival following BMT2. The incidence of grade >/=2 acute GVHD was low (14%). Eight of nine patients who received the new preparative regimen are alive, four without thalassemia. This study shows that BMT2 can be an effective therapy for a proportion of patients with poor survival expectancies despite conventional treatment.  (+info)

Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. (6/159)

Juvenile hemochromatosis is a rare genetic disorder that causes iron overload. Clinical complications, which include liver cirrhosis, heart failure, hypogonadotropic hypogonadism and diabetes, appear earlier and are more severe than in HFE-related hemochromatosis. This disorder, therefore, requires an aggressive therapeutic approach to achieve iron depletion. We report here the case of a young Italian female with juvenile hemochromatosis who was unable to tolerate frequent phlebotomy because of coexistent ss-thalassemia trait. The patient was successfully iron-depleted by combining phlebotomy with recombinant human erythropoietin.  (+info)

Lightening the lead load in children. (7/159)

More than 4 percent of preschool-aged children in the United States have blood lead levels above 10 microg per dL (0.50 pmol per L), and these levels have been associated with a decline in IQ. The Centers for Disease Control and Prevention advocates the use of a screening questionnaire to identify lead exposure or toxicity in all children. Primary prevention through the removal of lead from gasoline and paint has led to a reduction of blood lead levels in children. Secondary prevention through paint hazard remediation is effective in homes that have a high lead burden. Children with lead levels of 45 to 69 microg per dL (2.15 to 3.35 pmol per L) should receive chelation therapy using succimer (DMSA) or edetate calcium disodium (CaNa2EDTA). Use of both CaNa2EDTA and dimercaprol (BAL in oil) is indicated in children with blood lead levels higher than 70 microg per dL (3.40 micromol per L). Current treatment recommendations are based on the reduction of blood lead levels, which may not represent a significant overall reduction of the lead burden. Clinical trials of existing agents are needed to determine patient-oriented outcomes, such as the effect on IQ.  (+info)

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. (8/159)

This study introduces a method for monitoring a component of serum non-transferrin-bound iron (NTBI), termed "desferrioxamine-chelatable iron" (DCI). It is measured with the probe fluorescein-desferrioxamine (Fl-DFO), whose fluorescence is stoichiometrically quenched by iron. DCI was found in the serum of most patients with thalassemia major (21 of 27 tested, range 1.5-8.6 microM), but only in a minority of patients with hereditary hemochromatosis (8 of 95 samples from 39 patients, range 0.4-1.1 microM) and in none of 48 controls. The method was applied to monitoring the appearance of iron in the serum of patients under chelation therapy. Short-term (2 hours) follow-up of patients immediately after oral administration of deferriprone (L1) showed substantial mobilization of DCI into the serum (up to 10 microM within 30-60 minutes). The transfer of DCI from L1 to Fl-DFO was observed in vitro with preformed L1-iron complexes, and occurred even at L1/iron ratios exceeding 3:1. Simultaneous administration of oral L1 and intravenous DFO to patients abrogated the L1-mediated rise in DCI, consistent with the shuttling of iron from L1 to DFO in vivo. A similar iron transfer from L1 to apo-transferrin was observed in vitro, lending experimental support to the notion that L1 can shuttle iron in vivo to other high-affinity ligands. These results provide a rationale for using chelator combinations, with the highly permeant L1 acting as an intracellular chelator-shuttle and the less permeant DFO serving as an extracellular iron sink. Potential applications of the DCI assay may be for studying chelator action and as an index of patient chelation status.  (+info)

Chelation therapy is a medical treatment that involves the use of chelating agents to remove heavy metals and minerals from the body. A chelating agent is a molecule that bonds with the metal ions, forming a stable, water-soluble complex that can be excreted through urine or stool.

The most common chelating agent used in medical settings is ethylene diamine tetraacetic acid (EDTA), which is administered intravenously. EDTA binds with metals such as lead, mercury, iron, and calcium, and helps to eliminate them from the body.

Chelation therapy is primarily used to treat heavy metal poisoning, such as lead or mercury toxicity. It may also be used in some cases to treat cardiovascular disease, although its effectiveness for this use is still a matter of debate and controversy.

It's important to note that chelation therapy should only be administered under the supervision of a qualified healthcare professional, as improper use can lead to serious side effects and complications.

Iron chelating agents are medications that bind to iron in the body, forming a stable complex that can then be excreted from the body. These agents are primarily used to treat iron overload, a condition that can occur due to frequent blood transfusions or certain genetic disorders such as hemochromatosis. By reducing the amount of iron in the body, these medications can help prevent or reduce damage to organs such as the heart and liver. Examples of iron chelating agents include deferoxamine, deferasirox, and deferiprone.

Deferoxamine is a medication used to treat iron overload, which can occur due to various reasons such as frequent blood transfusions or excessive iron intake. It works by binding to excess iron in the body and promoting its excretion through urine. This helps to prevent damage to organs such as the heart and liver that can be caused by high levels of iron.

Deferoxamine is an injectable medication that is typically administered intravenously or subcutaneously, depending on the specific regimen prescribed by a healthcare professional. It may also be used in combination with other medications to manage iron overload more effectively.

It's important to note that deferoxamine should only be used under the guidance of a medical professional, as improper use or dosing can lead to serious side effects or complications.

Iron overload is a condition characterized by an excessive accumulation of iron in the body's tissues and organs, particularly in the liver, heart, and pancreas. This occurs when the body absorbs more iron than it can use or eliminate, leading to iron levels that are higher than normal.

Iron overload can result from various factors, including hereditary hemochromatosis, a genetic disorder that affects how the body absorbs iron from food; frequent blood transfusions, which can cause iron buildup in people with certain chronic diseases such as sickle cell anemia or thalassemia; and excessive consumption of iron supplements or iron-rich foods.

Symptoms of iron overload may include fatigue, joint pain, abdominal discomfort, irregular heartbeat, and liver dysfunction. If left untreated, it can lead to serious complications such as cirrhosis, liver failure, diabetes, heart problems, and even certain types of cancer. Treatment typically involves regular phlebotomy (removal of blood) to reduce iron levels in the body, along with dietary modifications and monitoring by a healthcare professional.

Chelating agents are substances that can bind and form stable complexes with certain metal ions, preventing them from participating in chemical reactions. In medicine, chelating agents are used to remove toxic or excessive amounts of metal ions from the body. For example, ethylenediaminetetraacetic acid (EDTA) is a commonly used chelating agent that can bind with heavy metals such as lead and mercury, helping to eliminate them from the body and reduce their toxic effects. Other chelating agents include dimercaprol (BAL), penicillamine, and deferoxamine. These agents are used to treat metal poisoning, including lead poisoning, iron overload, and copper toxicity.

Beta-thalassemia is a genetic blood disorder that affects the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. Specifically, beta-thalassemia is caused by mutations in the beta-globin gene, which leads to reduced or absent production of the beta-globin component of hemoglobin.

There are two main types of beta-thalassemia:

1. Beta-thalassemia major (also known as Cooley's anemia): This is a severe form of the disorder that typically becomes apparent in early childhood. It is characterized by a significant reduction or absence of beta-globin production, leading to anemia, enlarged spleen and liver, jaundice, and growth retardation.
2. Beta-thalassemia intermedia: This is a milder form of the disorder that may not become apparent until later in childhood or even adulthood. It is characterized by a variable reduction in beta-globin production, leading to mild to moderate anemia and other symptoms that can range from nonexistent to severe.

Treatment for beta-thalassemia depends on the severity of the disorder and may include blood transfusions, iron chelation therapy, and/or bone marrow transplantation. In some cases, genetic counseling and prenatal diagnosis may also be recommended for families with a history of the disorder.

Pyridones are a class of organic compounds that contain a pyridone ring, which is a heterocyclic ring consisting of a six-membered ring with five carbon atoms and one nitrogen atom, with one oxygen atom attached to the nitrogen atom by a double bond. Pyridones can be found in various natural sources, including plants and microorganisms, and they also have important applications in the pharmaceutical industry as building blocks for drug design and synthesis. Some drugs that contain pyridone rings include antihistamines, anti-inflammatory agents, and antiviral agents.

Lead poisoning is a type of metal poisoning caused by the accumulation of lead in the body, often over months or years. Even small amounts of lead can cause serious health problems. Children under the age of 6 are particularly vulnerable to lead poisoning, which can severely affect mental and physical development.

The primary source of lead exposure is lead-based paint and lead-contaminated dust in older buildings. Lead can also be found in water supplied through lead pipes, soil contaminated by historical industrial activity, air (in certain industries and locations), and some consumer products such as toys, cosmetics, and traditional medicines.

Lead poisoning can cause a wide range of symptoms, including developmental delays, learning difficulties, abdominal pain, irritability, fatigue, loss of appetite, weight loss, constipation, vomiting, and memory or concentration problems. In severe cases, it can lead to seizures, coma, and even death.

It's important to note that there is no safe level of lead exposure, and any amount of lead in the body is potentially harmful. If you suspect lead poisoning, consult a healthcare professional for evaluation and treatment options.

Edetic acid, also known as ethylenediaminetetraacetic acid (EDTA), is not a medical term per se, but a chemical compound with various applications in medicine. EDTA is a synthetic amino acid that acts as a chelating agent, which means it can bind to metallic ions and form stable complexes.

In medicine, EDTA is primarily used in the treatment of heavy metal poisoning, such as lead or mercury toxicity. It works by binding to the toxic metal ions in the body, forming a stable compound that can be excreted through urine. This helps reduce the levels of harmful metals in the body and alleviate their toxic effects.

EDTA is also used in some diagnostic tests, such as the determination of calcium levels in blood. Additionally, it has been explored as a potential therapy for conditions like atherosclerosis and Alzheimer's disease, although its efficacy in these areas remains controversial and unproven.

It is important to note that EDTA should only be administered under medical supervision due to its potential side effects and the need for careful monitoring of its use.

Benzoates are the salts and esters of benzoic acid. They are widely used as preservatives in foods, cosmetics, and pharmaceuticals to prevent the growth of microorganisms. The chemical formula for benzoic acid is C6H5COOH, and when it is combined with a base (like sodium or potassium), it forms a benzoate salt (e.g., sodium benzoate or potassium benzoate). When benzoic acid reacts with an alcohol, it forms a benzoate ester (e.g., methyl benzoate or ethyl benzoate).

Benzoates are generally considered safe for use in food and cosmetics in small quantities. However, some people may have allergies or sensitivities to benzoates, which can cause reactions such as hives, itching, or asthma symptoms. In addition, there is ongoing research into the potential health effects of consuming high levels of benzoates over time, particularly in relation to gut health and the development of certain diseases.

In a medical context, benzoates may also be used as a treatment for certain conditions. For example, sodium benzoate is sometimes given to people with elevated levels of ammonia in their blood (hyperammonemia) to help reduce those levels and prevent brain damage. This is because benzoates can bind with excess ammonia in the body and convert it into a form that can be excreted in urine.

Succimer is an medication, specifically a chelating agent, that is used to treat heavy metal poisoning, such as lead or mercury. It works by binding to the metal ions in the body and allowing them to be excreted through urine. The chemical name for succimer is dimercaptosuccinic acid (DMSA). It is available in the form of oral capsules and is typically prescribed by a healthcare professional.

In the context of medicine, iron is an essential micromineral and key component of various proteins and enzymes. It plays a crucial role in oxygen transport, DNA synthesis, and energy production within the body. Iron exists in two main forms: heme and non-heme. Heme iron is derived from hemoglobin and myoglobin in animal products, while non-heme iron comes from plant sources and supplements.

The recommended daily allowance (RDA) for iron varies depending on age, sex, and life stage:

* For men aged 19-50 years, the RDA is 8 mg/day
* For women aged 19-50 years, the RDA is 18 mg/day
* During pregnancy, the RDA increases to 27 mg/day
* During lactation, the RDA for breastfeeding mothers is 9 mg/day

Iron deficiency can lead to anemia, characterized by fatigue, weakness, and shortness of breath. Excessive iron intake may result in iron overload, causing damage to organs such as the liver and heart. Balanced iron levels are essential for maintaining optimal health.

Thalassemia is a group of inherited genetic disorders that affect the production of hemoglobin, a protein in red blood cells responsible for carrying oxygen throughout the body. The disorder results in less efficient or abnormal hemoglobin, which can lead to anemia, an insufficient supply of oxygen-rich red blood cells.

There are two main types of Thalassemia: alpha and beta. Alpha thalassemia occurs when there is a problem with the alpha globin chain production, while beta thalassemia results from issues in beta globin chain synthesis. These disorders can range from mild to severe, depending on the number of genes affected and their specific mutations.

Severe forms of Thalassemia may require regular blood transfusions, iron chelation therapy, or even a bone marrow transplant to manage symptoms and prevent complications.

A blood transfusion is a medical procedure in which blood or its components are transferred from one individual (donor) to another (recipient) through a vein. The donated blood can be fresh whole blood, packed red blood cells, platelets, plasma, or cryoprecipitate, depending on the recipient's needs. Blood transfusions are performed to replace lost blood due to severe bleeding, treat anemia, support patients undergoing major surgeries, or manage various medical conditions such as hemophilia, thalassemia, and leukemia. The donated blood must be carefully cross-matched with the recipient's blood type to minimize the risk of transfusion reactions.

Ferritin is a protein in iron-metabolizing cells that stores iron in a water-soluble form. It is found inside the cells (intracellular) and is released into the bloodstream when the cells break down or die. Measuring the level of ferritin in the blood can help determine the amount of iron stored in the body. High levels of ferritin may indicate hemochromatosis, inflammation, liver disease, or other conditions. Low levels of ferritin may indicate anemia, iron deficiency, or other conditions.

In the context of medicine, "lead" most commonly refers to lead exposure or lead poisoning. Lead is a heavy metal that can be harmful to the human body, even at low levels. It can enter the body through contaminated air, water, food, or soil, and it can also be absorbed through the skin.

Lead poisoning occurs when lead builds up in the body over time, causing damage to the brain, nervous system, red blood cells, and kidneys. Symptoms of lead poisoning may include abdominal pain, constipation, fatigue, headache, irritability, memory problems, and in severe cases, seizures, coma, or even death.

Lead exposure is particularly dangerous for children, as their developing bodies are more sensitive to the harmful effects of lead. Even low levels of lead exposure can cause learning disabilities, behavioral problems, and developmental delays in children. Therefore, it's important to minimize lead exposure and seek medical attention if lead poisoning is suspected.

Triazoles are a class of antifungal medications that have broad-spectrum activity against various fungi, including yeasts, molds, and dermatophytes. They work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased permeability and disruption of fungal growth. Triazoles are commonly used in both systemic and topical formulations for the treatment of various fungal infections, such as candidiasis, aspergillosis, cryptococcosis, and dermatophytoses. Some examples of triazole antifungals include fluconazole, itraconazole, voriconazole, and posaconazole.

Siderosis is a medical condition characterized by the abnormal accumulation of iron in various tissues and organs, most commonly in the lungs. This occurs due to the repeated inhalation of iron-containing dusts or fumes, which can result from certain industrial processes such as welding, mining, or smelting.

In the lungs, this iron deposit can lead to inflammation and fibrosis, potentially causing symptoms like coughing, shortness of breath, and decreased lung function. It is important to note that siderosis itself is not contagious or cancerous, but there may be an increased risk for lung cancer in individuals with severe and prolonged exposure to iron-containing particles.

While siderosis is generally non-reversible, the progression of symptoms can often be managed through medical interventions and environmental modifications to reduce further exposure to iron-containing dusts or fumes.

Mercury poisoning, also known as hydrargyria or mercurialism, is a type of metal poisoning caused by exposure to mercury or its compounds. It can occur through inhalation, ingestion, or skin absorption. Symptoms may vary but can include sensory impairment (vision, hearing, speech), disturbed sensation and a lack of coordination. The type of symptoms can vary greatly, depending on the type and amount of mercury and the form in which it was taken. Long-term exposure to mercury can lead to serious neurological and kidney problems. It is usually diagnosed through tests that measure the amount of mercury in the body, such as blood or urine tests. Treatment generally involves eliminating the source of mercury exposure, supportive care, and, in some cases, chelation therapy which helps to remove mercury from the body.

Hemosiderosis is a medical condition characterized by the abnormal accumulation of hemosiderin, an iron-containing protein, in various organs and tissues of the body. Hemosiderin is derived from the breakdown of hemoglobin, which is the oxygen-carrying protein in red blood cells. When there is excessive breakdown of red blood cells or impaired clearance of hemosiderin, it can lead to its accumulation in organs such as the liver, spleen, and lungs.

Hemosiderosis can be classified into two types: primary and secondary. Primary hemosiderosis is a rare condition that is caused by genetic disorders affecting red blood cells, while secondary hemosiderosis is more common and is associated with various conditions that cause excessive breakdown of red blood cells or chronic inflammation. These conditions include hemolytic anemias, repeated blood transfusions, liver diseases, infections, and certain autoimmune disorders.

The accumulation of hemosiderin can lead to tissue damage and organ dysfunction, particularly in the lungs, where it can cause pulmonary fibrosis, and in the heart, where it can lead to heart failure. Hemosiderosis is typically diagnosed through a combination of medical history, physical examination, and laboratory tests, including blood tests and imaging studies such as chest X-rays or MRI scans. Treatment of hemosiderosis depends on the underlying cause and may include medications, blood transfusions, or supportive care to manage symptoms and prevent complications.

Pythiosis is a rare but serious invasive infection caused by the aquatic oomycete pathogen Pythium insidiosum. This organism is not a true fungus, but is often treated as such in medical settings due to its similar clinical manifestations and response to antifungal therapies.

Pythiosis primarily affects animals, particularly horses, dogs, and cats, while human cases are relatively rare and usually associated with exposure through water-related activities or traumatic injuries. The infection typically occurs in tropical and subtropical regions, with a higher prevalence in Southeast Asia and Central America.

In humans, pythiosis can manifest as several forms: cutaneous, gastrointestinal, vascular, ocular, and disseminated. Cutaneous pythiosis usually presents as a painless, ulcerative skin lesion or subcutaneous nodule that may progress to form a necrotic tract or mass. Gastrointestinal pythiosis is characterized by inflammation, strictures, and abscesses in the intestines, leading to symptoms such as diarrhea, abdominal pain, and weight loss. Vascular pythiosis involves the formation of infectious thrombi or aneurysms in blood vessels, which can result in ischemia, infarction, or hemorrhage. Ocular pythiosis affects the eye, causing keratitis, scleritis, uveitis, or endophthalmitis. Disseminated pythiosis occurs when the infection spreads to multiple organs and tissues, resulting in a severe, life-threatening condition with high mortality rates.

Diagnosis of pythiosis is often challenging due to its rarity and nonspecific clinical presentation. A definitive diagnosis typically requires the isolation and identification of P. insidiosum from tissue samples or body fluids, followed by molecular confirmation using techniques such as polymerase chain reaction (PCR) or sequencing.

Treatment options for pythiosis are limited, with surgical resection being the primary approach to remove infected tissues and prevent disease progression. Antifungal agents such as azoles, echinocandins, and terbinafine have shown variable efficacy against P. insidiosum in vitro but may be used as adjunctive therapy in combination with surgery. Immunotherapy using a heat-killed P. insidiosum vaccine has also been reported to improve treatment outcomes in some cases.

Preventing exposure to P. insidiosum is crucial for reducing the risk of pythiosis, especially in high-risk populations such as immunocompromised individuals and those with underlying medical conditions. Avoiding contact with contaminated water sources, soil, or plant material, as well as practicing good hygiene and wound care, can help prevent infection.

Dimercaprol is a chelating agent, which means it can bind to and help remove certain toxic substances from the body. It is primarily used in the treatment of heavy metal poisoning, such as lead, mercury, or arsenic poisoning. Dimercaprol works by forming stable complexes with these toxic metals, allowing them to be excreted from the body through urine and bile.

The chemical name for dimercaprol is British Anti-Lewisite (BAL), as it was initially developed during World War II as an antidote against the chemical warfare agent Lewisite, a type of arsenic-based blistering agent. Dimercaprol is administered parenterally, usually by intramuscular injection, and its use requires medical supervision due to potential side effects, including hypertension, tachycardia, nausea, vomiting, and pain at the injection site.

Lead poisoning in adults refers to the harmful effects that occur due to elevated levels of lead in the body, particularly affecting the nervous system. Lead is a potent neurotoxin with no known safe level of exposure. In adults, chronic exposure to lead can result in a range of neurological symptoms, including cognitive impairment, memory loss, headaches, sleep disturbances, and peripheral neuropathy (nerve damage causing weakness, numbness, or pain in the hands and feet).

The primary source of lead poisoning in adults is occupational exposure, such as through mining, smelting, construction, manufacturing, or recycling activities. Lead can also enter the body through ingestion or inhalation of lead-contaminated dust, soil, water, or food. Adults with certain risk factors, including living in older homes with lead-based paint, engaging in hobbies that involve lead (e.g., stained glass making, pottery), or consuming traditional medicines or imported foods containing lead, are also at increased risk.

Diagnosis of lead poisoning in adults typically involves blood tests to measure the level of lead in the blood. Levels above 5 micrograms per deciliter (µg/dL) are considered elevated and may require medical intervention. Treatment for lead poisoning includes removing the source of exposure, providing supportive care, and, in some cases, administering chelation therapy to remove lead from the body. Prevention is key in reducing the risk of lead poisoning, including implementing safety measures at work, maintaining a healthy diet, and avoiding sources of lead exposure.

An erythrocyte transfusion, also known as a red blood cell (RBC) transfusion, is the process of transferring compatible red blood cells from a donor to a recipient. This procedure is typically performed to increase the recipient's oxygen-carrying capacity, usually in situations where there is significant blood loss, anemia, or impaired red blood cell production.

During the transfusion, the donor's red blood cells are collected, typed, and tested for compatibility with the recipient's blood to minimize the risk of a transfusion reaction. Once compatible units are identified, they are infused into the recipient's circulation through a sterile intravenous (IV) line. The recipient's body will eventually eliminate the donated red blood cells within 100-120 days as part of its normal turnover process.

Erythrocyte transfusions can be lifesaving in various clinical scenarios, such as trauma, surgery, severe anemia due to chronic diseases, and hematologic disorders. However, they should only be used when necessary, as there are potential risks associated with the procedure, including allergic reactions, transmission of infectious diseases, transfusion-related acute lung injury (TRALI), and iron overload in cases of multiple transfusions.

Siderophores are low-molecular-weight organic compounds that are secreted by microorganisms, such as bacteria and fungi, to chelate and solubilize iron from their environment. They are able to bind ferric iron (Fe3+) with very high affinity and form a siderophore-iron complex, which can then be taken up by the microorganism through specific transport systems. This allows them to acquire iron even in environments where it is present at very low concentrations or in forms that are not readily available for uptake. Siderophores play an important role in the survival and virulence of many pathogenic microorganisms, as they help them to obtain the iron they need to grow and multiply.

Myelodysplastic syndromes (MDS) are a group of diverse bone marrow disorders characterized by dysplasia (abnormal development or maturation) of one or more types of blood cells or by ineffective hematopoiesis, resulting in cytopenias (lower than normal levels of one or more types of blood cells). MDS can be classified into various subtypes based on the number and type of cytopenias, the degree of dysplasia, the presence of ring sideroblasts, and cytogenetic abnormalities.

The condition primarily affects older adults, with a median age at diagnosis of around 70 years. MDS can evolve into acute myeloid leukemia (AML) in approximately 30-40% of cases. The pathophysiology of MDS involves genetic mutations and chromosomal abnormalities that lead to impaired differentiation and increased apoptosis of hematopoietic stem and progenitor cells, ultimately resulting in cytopenias and an increased risk of developing AML.

The diagnosis of MDS typically requires a bone marrow aspiration and biopsy, along with cytogenetic and molecular analyses to identify specific genetic mutations and chromosomal abnormalities. Treatment options for MDS depend on the subtype, severity of cytopenias, and individual patient factors. These may include supportive care measures, such as transfusions and growth factor therapy, or more aggressive treatments, such as chemotherapy and stem cell transplantation.

Complementary therapies refer to a group of diverse medical and health care systems, practices, and products that are not presently considered an integral part of conventional allopathic medicine. They are often used in conjunction with conventional treatments and are intended to facilitate the physical and emotional well-being of the patient. Complementary therapies can include a wide range of interventions such as acupuncture, chiropractic care, massage therapy, herbal medicine, yoga, meditation, guided imagery, hypnotherapy, and homeopathy, among others. It is important to note that while some complementary therapies have been shown to be effective for certain conditions, others lack scientific evidence of their safety and efficacy. Therefore, it is always recommended to consult with a healthcare provider before starting any new complementary therapy.

I apologize, but "Alberta" is not a medical term. It is the name of a province in Canada, located in western Canada, and is known for its vast prairies, mountains, and coniferous forests. It is bordered by the provinces of British Columbia to the west and Saskatchewan to the east, as well as the Northwest Territories to the north, and the US state of Montana to the south.

If you have any questions related to medical terminology or health-related topics, I would be happy to try to help answer them for you.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

... in the Treatment of Metal Intoxication. Academic Press. p. 388. ISBN 9780128030721. "Chelation: Therapy or " ... Over-the-counter chelation products are not approved for sale in the United States. Chelation therapy is the preferred medical ... NCCAM Director Stephen E. Straus cited the "widespread use of chelation therapy in lieu of established therapies, the lack of ... In response to increasing use of chelation therapy as alternative medicine and in circumstances in which the therapy should not ...
... is useful in applications such as providing nutritional supplements, in chelation therapy to remove toxic metals from ... Disodium EDTA is not approved by the FDA for any use, and all FDA-approved chelation therapy products require a prescription. ... "FDA Issues Chelation Therapy Warning". September 26, 2008. Retrieved May 14, 2016. Centers for Disease Control Prevention (CDC ... Dechelation (or de-chelation) is a reverse process of the chelation in which the chelating agent is recovered by acidifying ...
"Chelation Therapy". American Cancer Society. 2008. Retrieved 2014-04-28. "Chelation: Therapy or "Therapy"?". National Capital ...
Practices Chelation Therapy. Has an interest in meditation and nutritional supplements. A member of a non-violent social action ... In 2001, Faye's therapy massage centre was awarded SEED Winnipeg's Community Development Business Award. She herself is a ...
Chelation therapy "Deferoxamine Mesylate". The American Society of Health-System Pharmacists. Archived from the original on 21 ... Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM (July 2018). "The effect of iron chelation therapy on overall survival in ... Zeng L, Tan L, Li H, Zhang Q, Li Y, Guo J (2018). "Deferoxamine therapy for intracerebral hemorrhage: A systematic review". ... Abobaker A (November 2020). "Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?". European ...
She has promoted the disproven idea that vaccines cause autism, and said that chelation therapy, a quack remedy, helped cure ... McCarthy has claimed on talk shows and at rallies that chelation therapy helped her son recover from autism. The underlying ... "Chelation Therapy for Autism is Quackery". September 5, 2018. Retrieved December 1, 2019. Sinha, ... "Chelation therapy and autism". BMJ: British Medical Journal. 333 (7571): 756. doi:10.1136/bmj.333.7571.756. ISSN 0959-8138. PMC ...
"Chelation Therapy: AHA recommendations". American Heart Association. Archived from the original on 19 April 2008. Immunization ... In medieval Persia, Avicenna (980-1037 CE), the 'Prince of Doctors', wrote about clay therapy in his numerous treatises. Ibn al ... It has been used as a scientifically unsupported chelation treatment for heart disease and autism. Bentonite has the ability to ... Guin, JD (2001). "Treatment of toxicodendron dermatitis (poison ivy and poison oak)". Skin Therapy Letter. 6 (7): 3-5. PMID ...
Britton RS, Leicester KL, Bacon BR (October 2002). "Iron toxicity and chelation therapy". International Journal of Hematology. ...
Gracia, RC; Snodgrass, WR (1 January 2007). "Lead toxicity and chelation therapy". American Journal of Health-System Pharmacy. ...
Chelation therapy is administered under very careful medical supervision due to various inherent risks. Even when the therapy ... An option for treatment of metal poisoning may be chelation therapy, a technique involving the administration of chelation ... Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the ... Chelation therapy does not improve outcomes for those diseases. "A Metals Primer". Dartmouth Toxic Metals Superfund Research ...
Chelation therapy is of limited value for cases of chronic exposure to low levels of lead. Chelation therapy is usually stopped ... known as chelation therapy. Chelation therapy in children is recommended when blood levels are greater than 40-45 µg/dl. ... It is also important to note that chelation therapy only lowers blood lead levels and may not prevent the lead-induced ... Although the technique has been used to determine whether chelation therapy is indicated and to diagnose heavy metal exposure, ...
Chelation therapy Detoxification Pirmohamed, Dr Munir; Kitteringham, Neil R.; Park, B. Kevin (2012-10-26). "The Role of Active ...
... and approaches to iron chelation therapy. Published medical research funded in whole or in part by the Foundation includes: "A ... Medical research considered for funding includes clinical trials in cell and gene therapies, and ongoing clinical projects with ... and gene therapy as potential curative approaches to thalassemia; vector development; nutritional requirements in thalassemia; ... nurses and others involved in thalassemia care and research to share information and learn about up-to-date therapies and ...
... being provided with Iron chelation therapy. Efforts are under-way to collect funds and start provision of Iron chelation ... therapy to all registered patients. The cost of treatment of one patients with this lifelong disease is Pakistani Rs. 300,000 ...
Although critics of using chelation therapy as an autism treatment point to a lack of any evidence to support its use, hundreds ... "Why Chelation Therapy Should Be Avoided". Quackwatch. 15 May 2004. Retrieved 7 October 2013. Stokstad E (2008). "Stalled trial ... A 5-year-old autistic boy died from cardiac arrest immediately after receiving chelation therapy treatment using EDTA in 2005. ... In 2004 Quackwatch posted an article saying that chelation therapy has been falsely promoted as effective against autism, and ...
For more severe forms, treatment may consist in blood transfusion; chelation therapy to reverse iron overload, using drugs such ... This iron overload may be treated with chelation therapy. Deferoxamine, deferiprone and deferasirox are the three most widely ... Galanello, R.; Campus, S. (2009). "Deferiprone Chelation Therapy for Thalassemia Major". Acta Haematologica. 122 (2-3): 155-64 ... Zinc chelation may cause zinc deficiency in the body, which can thus lead to a reduced growth rate, reduced collagen formation ...
He was subsequently treated with chelation therapy. It is likely that the medical care which he was given saved his life; ...
Chelation therapy removes iron from the blood. This involves delivering iron chelating agents such as deferoxamine, deferiprone ... Tissue damage can remain even after chelation therapy. Outcomes are usually worse in patients who require blood transfusions ... It is treated with venipuncture, erythrocytapheresis, and iron chelation therapy. Transfusional hemosiderosis can cause cardiac ... Borgna-Pignatti, C; Castriota-Scanderbeg, A (September 1991). "Methods for evaluating iron stores and efficacy of chelation in ...
This iron overload may require chelation therapy. The global market for anemia treatments is estimated at more than USD 23 ... A paradigm shift towards gene therapy and monoclonal antibody therapies are observed. Nutritional iron deficiency is common in ... Intramuscular therapy leads to more rapid improvement and should be considered in patients with severe deficiency or severe ... "Global Iron-Deficiency Anemia Therapy Market - Industry Trends and Forecast to 2027 -". Data Bridge Market Research. Retrieved ...
Wilson's disease is managed by copper chelation therapy with D-penicillamine (which picks up and binds copper and enables ... Baldari, Silvia; Di Rocco, Giuliana; Toietta, Gabriele (2020). "Current biomedical use of copper chelation therapy". Int J Mol ... Zinc therapy is now the treatment of choice. Zinc produces a mucosal block by inducing metallothionein, which binds copper in ... Adjusting copper levels in the diet or drinking water will not cure these conditions (although therapies are available to ...
"EDTA Chelation Therapy for the Treatment of Neurotoxicity". International Journal of Molecular Sciences. 20 (5): 1019. doi: ... Swaran J.S. Flora; Vidhu Pachauri (June 2010). "Chelation in Metal Intoxication". International Journal of Environmental ...
ASAT has warned against chelation therapy as an autism treatment, noting that two children have been reported to have died as a ... "Chelation Therapy-Association for Science in Autism Treatment". Archived from the original on 2013-10-29. Retrieved 2013-10-20 ... Herbs and Homeopathic Treatments Archived October 29, 2013, at the Wayback Machine Animal therapy Archived October 25, 2013, at ... Treatments they consider to be unproven, rather than disproven, include homeopathy and animal therapy. Published research ...
At 45 µg/dL, chelation therapy is considered. Among the many ways lead can enter a modern American's bloodstream is through ...
... that aversion therapy and the use of restraints are physically harmful, and that alternative treatments like chelation therapy ... "British Boy Dies After Chelation Therapy for Autism". 26 August 2005. Archived from the original on 16 ... testified in court against government funding of ABA therapy. An autistic person named Jane Meyerding criticized therapy which ... Aspies For Freedom (AFF) stated that the most common therapies for autism are unethical, since they focus on extinguishing ...
Despite aggressive chelation therapy, her condition rapidly deteriorated. Three weeks after the first neurological symptoms ...
It is difficult or impossible to interpret urine samples of people undergoing chelation therapy, as the therapy itself ... Hazards of chelation therapy: Brown MJ, Willis T, Omalu B, Leiker R (August 2006). "Deaths resulting from hypocalcemia after ... Chelation therapy can cause a transient elevation of urine mercury levels. Neolithic artists using cinnabar show signs of ... Chelation therapy for acute inorganic mercury poisoning, a formerly common method, was done with DMSA, 2,3-dimercapto-1- ...
ISBN 978-0-8493-1029-4. Walker, M.; Shah, H.H. (1997). Everything you should know about chelation therapy (4th ed.). New Canaan ... Chelation therapy is a form of medical treatment in which a chelating ligand is used to selectively remove a metal from the ... Chelation occurs with the two oxygen atoms. Wilson's disease is caused by a defect in copper metabolism which results in ... naturally occurring siderophore produced by the actinobacter Streptomyces pilosus and was used initially as a chelation therapy ...
Treatment consists of frequent blood transfusions and chelation therapy. Potential cures include bone marrow transplantation ... and gene therapy. Congenital dyserythropoietic anemia Thalassemia Hemoglobinopathy List of hematologic conditions "Congenital ...
Treatment consists of frequent blood transfusions and chelation therapy. Potential cures include bone marrow transplantation ... and gene therapy.[citation needed] Congenital dyserythropoietic anemia Thalassemia Hemoglobinopathy List of hematologic ...
"Oral Chelation Therapy for Patients with Lead Poisoning" (PDF). World Health Organization. Retrieved April 10, 2017. Hummer, ... For extremely high blood lead levels (i.e., BLLs ≥ 45 µg/dL), chelation therapy may recommended for refugee children. The CDC ... Experts have found that drug therapy, through the use of serotonin uptake inhibitors, as well as cognitive therapy have been ...
Chelation Therapy in the Treatment of Metal Intoxication. Academic Press. p. 388. ISBN 9780128030721. "Chelation: Therapy or " ... Over-the-counter chelation products are not approved for sale in the United States. Chelation therapy is the preferred medical ... NCCAM Director Stephen E. Straus cited the "widespread use of chelation therapy in lieu of established therapies, the lack of ... In response to increasing use of chelation therapy as alternative medicine and in circumstances in which the therapy should not ...
IV chelation therapy (chemical endarterectomy) S9355. Home infusion therapy, chelation therapy; administrative services, ... patient NIH-sponsored Assess Chelation Therapy 2 (TACT2) Trial, which may help clarify if chelation therapy truly represents a ... Fortunately, iron overload and organ damage can be prevented with chelation therapy …. There are currently 2 chelation drugs ... to Assess Chelation Therapy investigators concluded that their results did not support the routine use of chelation therapy for ...
We go over the process and costs associated with chelation therapy before diving into its proven and unproven benefits. ... Chelation therapy removes heavy metals from the bloodstream. Its a very effective treatment for heavy metal poisoning. But can ... Chelation: Therapy or "therapy"? (n.d.).. ... of chelation therapy in children with autism.. They made the decision after an animal study. in rats showed that chelation ...
... effective therapy for autism spectrum disorder (8). Because limited consistent data exist on the use of chelation therapy to ... chelation therapy for children is CaEDTA (1). However, hospital formularies usually stock multiple chelation agents. One such ... Chelation therapy with CaEDTA, dimercaperol, or succimer has been the mainstay of medical management for children with BLLs ,45 ... Pennsylvania. In August 2005, a boy aged 5 years with autism died while receiving IV chelation therapy with Na2EDTA in a ...
PlacidWay help you to get best chelation therapy on affordable price and provide you lots of packages to select best one. ... Chelation Therapy - Alternative Medicine. Chelation Therapy, Alternative Medicine, Holistic Medicine, How Chelation Therapy ... Chelation Therapy Treatment Abroad. Overview. Chelation therapy is considered a type of alternative or holistic medicine that ... How Much Does Chelation Therapy Cost?. In the United States, chelation therapy may range between $75 and $125 per treatment. ...
IV Therapy and IV & Chelation TherapiesPip2023-06-12T22:35:42+00:00 IV Therapy and IV & Chelation Therapies. A naturopathic ... IV & Chelation Therapies Certification. Certification in IV & chelation therapy requires:. *CNPBC certification in IV Therapy; ... Chelation Therapies Certification:. Registrants who hold IV & Chelation Therapies Certification may restore their IV Therapy ... In order to apply for and maintain certification in IV therapy or IV & chelation therapies, naturopathic physicians must hold ...
Chelation Therapy. Treatment Overview. Chelation therapy is a chemical process in which a medicine is injected into the ... Chelation is a very effective way to treat heavy metal poisoning. At high levels, heavy metals and minerals such as lead, ... Chelation means "to grab" or "to bind." When the medicine is injected into the veins, it "grabs" heavy metals and minerals such ... Chelation is used to lower the amount of heavy metals and minerals in the body. ...
Re: an analysis of the Green Zeolite Clay by goldhunter ..... Chelation Therapy Support Forum ...
Chelation therapy with EDTA and high-dose vitamin therapy both would be superior to placebo in post-MI patients. ... Chelation Therapy, Lipoproteins, LDL, Complementary Therapies, Heart Failure, Glomerular Filtration Rate, Hypocalcemia, Smoking ... Based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in Trial to Assess Chelation Therapy ... Chelation therapy for the treatment of CAD has been a controversial topic. The results of this trial are surprising since all ...
I will keep you posted! You could also use a mortar and pestal to grind the pills to powder to reduce the dose.
Chelation therapy is an enigma to most of the medical community. Many medical doctors oppose the use of Chelation therapy ... which is the basis for Chelation therapy. Simply put, chelation is the process of intravenously injecting a chelating agent (in ... Chelation therapy, performed on an outpatient basis at the doctors office, is a safe and effective treatment for heavy metal ... The history of Chelation therapy started about 100 years ago with Nobel Prize winner, Alfred Werner. Werner, a Swiss chemist, ...
Cookies This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy ...
Q: How does oral chelation compare to intravenous chelation therapy?. A: They basically do somewhat different things and even ... world-renown expert on chelation therapy, anti-aging, nutrition, mineral metabolism, and alternative and preventive therapies, ... Garry Gordon Discusses EDTA Oral Chelation Therapy. "I havent had to send one patient to a heart surgeon for the past 10 years ... This fact alone makes chelation therapy a benefit for virtually everyone. Nitric oxide (NO) protects the heart, stimulates the ...
This means there is no evidence that chelation therapy, which can lead to kidney failure or death, has any effect on autism ... Some children with autism have been subjected to chelation therapy, which is used to remove heavy metals from the blood after ... No Evidence Chelation Therapy Can Treat Autism. June 19, 2015 · Posted in Current Treatments ... A recent review of research on chelation therapy for autism by the Cochrane Collaboration, a nonprofit health research ...
The other forms of therapy used in treating psoriasis are light therapy, oral and topical medications. ... Chelation therapy is used by some to treat psoriasis although its use in this condition and in general remains controversial. ... Chelation Therapy For Psoriasis Treatment: Psoarisis Light Therapy. Question: Will chelation therapy help a 21 yr old girl ... Now chelation therapy can also be given in oral form.. Use Of Chelation Therapy For Psoriasis. The rational behind the use of ...
... chelation therapy has been considered a definitive alternative therapy for by-pass surgery in atherosclerotic cardiovascular ... Thus, EDTA chelation therapy as prescribed by the ACAM protocol seems safe and effective in improving exercise tolerance in ... However, the benefits of chelation therapy yet remain controversial in the treatment of ischemic heart disease. We observed the ... The recognized side effects of intravenous EDTA chelation therapy such as liver damage, renal damage, hypersensitivity, ...
But, say chelation advocates, no one has died from chelation therapy in decades until now. Well, thats not entirely true. ... chelation therapy for this purpose should be considered at best an experimental therapy (at worst it is a completely ... chelation therapy definitely fits that description. Indeed, chelation is touted as a treatment for atherosclerotic coronary ... Sadly, it was only a matter of time: An autistic boy dies during chelation therapy I started my vacation out with a bit of a ...
Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs--meso-dimercaptosuccinic acid (DMSA) ... Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury Chem Res ... Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs--meso-dimercaptosuccinic acid (DMSA) ... theory calculations to investigate the chemistry of interaction of mercuric ions with each of these chelation therapy drugs. We ...
Chelation Therapy - Learn about the causes, symptoms, diagnosis & treatment from the MSD Manuals - Medical Consumer Version. ... Chelation therapy with EDTA has also been suggested as a way to remove calcium and thus treat atherosclerosis Atherosclerosis ... Practitioners of chelation therapy believe that many disorders are caused by having too much of a metal in the body even when ... Side effects of chelation therapy to remove calcium include a low level of calcium, which can be serious and rarely is fatal. ...
Natural chelation therapy is healthier! Surely all top doctors can agree on this:. natural chelation therapy is healthier, ... Medicardium - Chelation Therapy - EDTA. Welcome to The 1 Shortcut Living Class, with Now running into millions of healthy, ... Natural chelation therapy, as recommended by top doctors of natural medicine,. top doctors of naturopathy and natural healing, ... Healthier Chelation Index Back to 1 Shortcut Living Class 1 Shortcut Living Class ...
MDs video on How can chelation therapy help a child with autism?... ... How can chelation therapy help a child with autism?. Watch Jerry Kartzinel, MDs video on How can chelation therapy help a ... Watch Jerry Kartzinel, MDs video on How can chelation therapy help a child with autism?... ...
Chelation Therapy. By Anonymous User is a CAM biologic/orthomolecular therapy involving the injection of ethylene diamine ... therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the ...
Who need Chelation Therapy?. *People who have risk an increased rick of coronary artery such as dental amalgam fillings, high ... Who need Chelation Therapy?. *People who have risk an increased rick of coronary artery such as dental amalgam fillings, high ... Chelation Therapy. (120 minutes) Panacee Wellness Khaoyai Khaoyai, Nakhon Ratchasima * 2,990.00 ฿ 2,990.00 ฿ small.price{ font- ... Chelation Therapy. "Removing Heavy Metal, Reviving Blood Vessels and Improving Circulation to Restore Your Health.". Today we ...
... is used to treat a variety of conditions, including heavy metal toxicity, cardiovascular, autoimmune, and ... Frequently Asked Questions about Chelation Therapy. What is Chelation Therapy?. Chelation therapy aims to bind minerals or ... Conditions Treated by Chelation Therapy. Here are some of the common conditions we use Chelation Therapy for:. *Heavy Metal ... Try Chelation Therapy. At Anatara Medicine, we strongly believe that chelation therapy can be a valuable tool in treating heavy ...
Categorized as Autism Therapy Tagged autism treatment therapy, chelation therapy, chelation therapy for lead, chelation therapy ... Tag: chelation therapy for lead. Chelation Therapy And Autism. Chelation is the process whereby chelating agents, chemical ... While the chelation therapy works for these specific ailments, the FDA has not approved the therapy for any other use than what ... Extreme cases of chelation overdose have caused severe… Continue reading Chelation Therapy And Autism ...
Could you provide studies that prove chelation therapy efficiency?. Of course! Chelation therapies have been long recognized as ... What is chelation therapy?. A therapy that uses ligating substances to chemically bond with toxic heavy metals, then get ... How is the chelation therapy given?. It can be administered via IV, rectally and orally. EDTA is most commonly given via IV ... What is the principle behind chelation therapy?. The use of chelating substances that chemically bond with toxins, get carried ...
Pros and Cons of Chelation Therapy. Despite the benefits, EDTA chelation does have its detractors. They argue that the results ... EDTA Chelation Therapy. EDTA (EthyleneDiamineTetraAcetic Acid) is a synthetic amino acid that acts as a powerful chelating ... Chelation Therapy and Blood Pressure. While severe cases of high blood pressure is generally characterized by symptoms such as ... Chelation therapy can improve health by removing excessive levels of toxic minerals in the body. These include, lead, nickel, ...
  • Cardio Renew is the leader in offering a safe, effective and affordable Oral Chelation Therapy . (
  • The patient was treated with intramuscular, intravenous, and oral chelation therapy to promote lead excretion. (
  • In 2005 , for example, a five-year-old boy with autism died while receiving intravenous EDTA from his doctor as part of chelation therapy. (
  • The only agent recommended for intravenous (IV) chelation therapy for children is CaEDTA ( 1 ). (
  • Abubakar Tariq Nadama died while receiving chelation therapy, an intravenous injection of a synthetic amino acid that latches onto heavy metals and is then passed in the urine. (
  • Chelation therapy involves the intravenous infusion of vitamins, magnesium, saline solution and the amino acid, EDTA. (
  • Now patients who were unable to come to the office regularly, patients with more advanced renal disease, and patients unable or unwilling to tolerate intravenous application of EDTA, are able to obtain chelation with as good or better results than the present IV method. (
  • It may also be given by continuous intravenous infusion to try and reverse cardiac failure when previous chelation has failed. (
  • When used properly in response to a diagnosis of harm from metal toxicity, side effects of chelation therapy include dehydration, low blood calcium, harm to kidneys, increased enzymes as would be detected in liver function tests, allergic reactions, and lowered levels of dietary elements. (
  • Aetna considers the dimercaptosuccinic acid (DMSA) or ethylenediaminetetraacetic (EDTA) provocative chelation/mobilization test experimental and investigational as a means of diagnosing lead toxicity because of insufficient evidence of its effectiveness. (
  • DMPS - IV push form of chelation therapy, used mainly as a diagnostic method of determining toxicity of heavy metals in the body. (
  • Chelation therapy, performed on an outpatient basis at the doctor's office, is a safe and effective treatment for heavy metal toxicity. (
  • If you have this toxicity, Chelation therapy can be a new turning point for your pursuit of wellness. (
  • Chelation Therapy is used to treat a variety of conditions, including heavy metal toxicity and cardiovascular, autoimmune, and neurodegenerative diseases. (
  • Anatara Medicine uses Chelation therapy to treat various health conditions, including heavy metal toxicity and cardiovascular, autoimmune, and neurodegenerative diseases. (
  • At Anatara Medicine, we strongly believe that chelation therapy can be a valuable tool in treating heavy metal toxicity and various health conditions. (
  • If you are experiencing symptoms of heavy metal toxicity or have been diagnosed with cardiovascular disease, we urge you to consider chelation therapy as a treatment option. (
  • Learn how Chelation Therapy can help you to get rid of heavy metal toxicity and achieve your health-goals. (
  • In this lecture, Dr. Lamas will discuss his research exploring the effects of chelation therapy on coronary heart disease. (
  • To avoid mobilization, some practitioners of chelation use strong chelators, such as selenium, taken at low doses over a long period of time. (
  • Chelation therapy has a long history of use in clinical toxicology and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks, including the mobilization of mercury and other metals through the brain and other parts of the body by the use of weak chelating agents that unbind with metals before elimination, exacerbating existing damage. (
  • Discuss pros and cons with family health providers, and inquire about combining alternative or holistic therapies with conservative or traditional forms of treatments for treatment of chronic degenerative diseases . (
  • Together, these treatments can have added benefits that a single therapy couldn't accomplish alone. (
  • Barbara Sonnenburg asked Peggy Adkins whether the treatments were chelation treatments and whether there were any side effects from those treatments. (
  • Peggy Adkins responded that they were chelation treatments, initially three times per week in Knoxville, now two times per week in Athens. (
  • Because of complaints of continued poor mental function, neuropsychological tests were administered before and after one of the chelation treatments and showed improvement in measures of attention and other cognitive domains. (
  • In recent years, some people have claimed that chelation therapy can also help to treat many other conditions, including heart disease, autism, Alzheimer's disease, and diabetes. (
  • In addition, a 2012 review of studies looking at the link between autism and mercury concluded there wasn't enough evidence that chelation therapy is an effective treatment for autism. (
  • Still, using chelation therapy to treat autism in children appears to do more harm than good. (
  • In 2006, the U.S. National Institute of Mental Health decided to cancel its study of chelation therapy in children with autism. (
  • Some children with autism have been subjected to chelation therapy, which is used to remove heavy metals from the blood after poisoning. (
  • The rationale for using this therapy in autism was the discredited theory that autism resulted from mercury poisoning. (
  • A recent review of research on chelation therapy for autism by the Cochrane Collaboration, a nonprofit health research organization, found only one randomized controlled trial of chelation therapy, which had a flawed methodology and also found no evidence of a reduction in autism symptoms. (
  • This means there is no evidence that chelation therapy, which can lead to kidney failure or death, has any effect on autism symptoms . (
  • Based on the lack of evidence that the therapy has benefits for children with autism spectrum disorders, its great expense, and the dangers it poses, chelation therapy should not be prescribed as a treatment for autism. (
  • If you accept that premise that mercury exposure during infancy causes autism, then chelation therapy sounds reasonable. (
  • How can chelation therapy help a child with autism? (
  • Watch Jerry Kartzinel, MD's video on How can chelation therapy help a child with autism? (
  • Research studies investigating the implications of chelation therapy on autism and neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, macular degeneration, rheumatoid arthritis, and others have been published. (
  • The purpose of chelation is to bind ("chelate") heavy metals with a molecule that allows them to be secreted more rapidly in the urine. (
  • A therapy that uses ligating substances to chemically bond with toxic heavy metals, then get carried to the digestive system to finally be excreted either through urine or feces. (
  • Chelation therapy is a treatment used to detoxify the body of toxic heavy metals, such as mercury, lead, aluminum, arsenic, and cadmium, by binding them (as they are stored in different types of tissue in the body such as thyroid and nervous system) and carrying them out of the body in the urine. (
  • That test involves administering a Chelation IV (EDTA and DMPS) followed by a 6 hour urine collection. (
  • Chelation therapy aims at reducing this iron burden by promoting iron excretion in the urine or faeces, or both. (
  • Chelation generally removes excess stores of minerals like lead, magnesium, iron, copper and calcium from the bloodstream, improving blood flow and circulation. (
  • What most likely happened in Abubakar's case is that he suffered a fatal arrhythmia due to hypocalcemia brought on by chelation of the calcium ions in his bloodstream. (
  • Side effects of chelation therapy to remove calcium include a low level of calcium, which can be serious and rarely is fatal. (
  • It can remove excess particles of calcium and plaque from the arterial walls.In the chelation process, EDTA removes the calcium and fat deposits that obstruct the blood vessel. (
  • Chelation Therapy helps to clear arteries of built up calcium plaque and remove heavy metals from the bloodstream, but how effective is it when taken orally? (
  • IV Chelation therapy may include an IV drip containing ethylene diamine tetra-acetic acid (EDTA), a synthetic amino acid that can help to remove heavy metal poisoning and toxic heavy metals such as iron, lead, copper, and calcium from the blood. (
  • Chelation clears heavy metals, excess calcium and artery-damaging chemicals from the bloodstream, bringing your body back to optimum health. (
  • Children who are symptomatic with elevated BLLs above 45 µg/dL may require hospital admission for monitoring and chelation therapy using medications such as succimer, dimercaprol, or edetate calcium disodium (EDTA). (
  • Chelation therapy with disodium ethylene diamine tetra acetic acid (EDTA) is sometimes suggested as an alternative medicine approach to the treatment of coronary artery disease (CAD). (
  • Chelation therapy is done with EDTA, or Ethylene diamine tetra acetic acid, which is an FDA-approved drug that acts as an amino acid. (
  • Chelation therapy can be traced back as far as the 1930s when Ferdinand Munz (a German chemist who worked for I.G. Farben, first synthesized Ethylene Diamine Tetra Acetic acid (EDTA). (
  • Chelation is believed to help remove toxins from the body that increase and enhance the body's own ability to heal itself. (
  • By eliminating these heavy metals and other toxins, chelation therapy can reduce oxidative stress and inflammation associated with a wide range of health issues. (
  • Chelation therapy is the preferred medical treatment for metal poisoning, including acute mercury, iron (including in cases of sickle-cell disease and thalassemia), arsenic, lead, uranium, plutonium and other forms of toxic metal poisoning. (
  • Chelation therapy is a method for removing heavy metals, such as mercury or lead , from blood. (
  • You can read more about reversing mercury poisoning through chelation therapy in our article. (
  • Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs--meso-dimercaptosuccinic acid (DMSA) and dimercaptopropanesulfonic acid (DMPS), commercially sold as Chemet and Dimaval, respectively. (
  • We have used a combination of mercury L(III)-edge X-ray absorption spectroscopy and density functional theory calculations to investigate the chemistry of interaction of mercuric ions with each of these chelation therapy drugs. (
  • Chelation is the process whereby chelating agents, chemical powders ingested into the body, remove high levels of toxic metals such as lead and mercury. (
  • Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the body. (
  • Chelation therapy is designed to remove excess heavy metals from the body, reducing the damaging effect free radicals can have on body organs. (
  • Chelation therapy has long been used and recognized as a treatment to remove toxic levels of metals, such as lead, from the body, in cases of suspected lead poisoning. (
  • Chelation therapy is a chemical process in which a medicine is injected into the bloodstream to remove heavy metals and/or minerals from the body. (
  • Chelation is used to lower the amount of heavy metals and minerals in the body. (
  • Simply put, chelation is the process of intravenously injecting a chelating agent (in liquid form) that bonds with specific toxic metals. (
  • Chelation is effective for many unexplainable illnesses because after the heavy metals are extracted from a contaminated body, normal physiological functions can be restored. (
  • Chelation removes toxic heavy metals that damage the walls of our blood vessels, mainly via urination. (
  • Chelation is the process by which toxic metals are removed from the body. (
  • Chelation (Key-ley-shun) therapy means using medication to remove certain toxic metals (including lead) and other toxic substances from the body. (
  • Chelation therapy was approved by the FDA for the removal of heavy metals. (
  • The chemical process where a synthetic solution called EDTA (ethylenediaminetetraacetic acid) is injected into the bloodstream to remove heavy metals or minerals from the body is called Chelation. (
  • Chelation can be administered through an IV or orally (less common) with specific chelating agents - EDTA and DMPS, each of which has affinity for different type of heavy metals. (
  • How do I know if I have heavy metals and need Chelation Therapy? (
  • Chelation Therapy is a safe, effective method of helping the body to detoxify and eliminate heavy metals from the body. (
  • IV chelation therapy is one form of detox we administer that involves the infusion of chemical substances that bind to certain excess toxic heavy metals and minerals in the bloodstream and removes them from the body. (
  • The therapy works by utilizing a chelating agent (also known as a chelator) which binds to the excess metals in the patient's bloodstream. (
  • One major benefit of this therapy is that it removes harmful excess metals from the body. (
  • You may be a good candidate for both therapies if you want to rid your body of excess metals and infuse it with more vitamins, minerals, and antioxidants. (
  • Chelation therapy is safe and effective in removing heavy metals from the body. (
  • While this seems logical, there's very little evidence that chelation therapy helps. (
  • Chelation therapy involves injecting a type of medication called a chelator or chelating agent. (
  • EDTA chelation therapy also involves nutrients such as B-complex vitamins, vitamin C and magnesium. (
  • Chelation" (pronounced key-lay-shun) is derived from "chelos," the Greek word for claw. (
  • Chelation (pronounced key-LAY-shun) therapy is a treatment used in conventional medicine for remov. (
  • The most common condition worldwide requiring iron chelation therapy is beta-thalassaemia major, but a proportion of patients with other inherited anaemias (eg, sickle cell anaemia) or with acquired transfusion-dependent anaemias (eg, myelodysplasia, myelofibrosis or aplastic anaemia) also require iron chelation therapy. (
  • To prevent this damage, doctors use iron chelation therapy to remove excess iron from the body. (
  • Two medicines are used for iron chelation therapy. (
  • Your doctor may recommend folic acid supplements in addition to treatment with blood transfusions and/or iron chelation therapy. (
  • Deferoxamine (DFO) is inactive by mouth, but it has been the mainstay of iron-chelating treatment since regular subcutaneous infusion therapy with DFO was introduced in 1976. (
  • Specifically, chelation has provoked a lot of antagonism in the medical community for its use in avoiding bypass surgery for cardiovascular problems. (
  • EDTA chelation therapy has become very popular these days as a safe and effective alternative to angioplasty and bypass surgery. (
  • Some people advocate using chelation therapy to treat atherosclerosis , which causes a buildup of plaque in arteries. (
  • Chelation therapy is considered a type of alternative medicine commonly used to treat chronic degenerative disease processes such as arthritis , atherosclerosis, and other disease processes that affect connective tissues. (
  • Chelation therapy is a safe and effective therapy to restore vascular health in cases of atherosclerosis without surgery. (
  • The chelator used in the therapy will be in the form of either a medication or a natural amino acid. (
  • In the 1950s, Norman Clarke, Sr. was treating workers at a battery factory for lead poisoning when he noticed that some of his patients had improved angina pectoris following chelation therapy. (
  • Clarke subsequently administered chelation therapy to patients with angina pectoris and other occlusive vascular disease and published his findings in The American Journal of the Medical Sciences in December 1956. (
  • During the past 30 years, environmental and dietary exposures to lead have decreased substantially, resulting in a considerable decrease in population blood lead levels (BLLs) ( 2 ) and a corresponding decrease in the number of patients requiring chelation therapy. (
  • As chelation therapy is considered an alternative or holistic practice, patients should carefully consider the benefits and drawbacks of such therapies. (
  • The current trial sought to compare outcomes with EDTA versus placebo infusion in post-myocardial infarction (MI) patients treated with medical therapy. (
  • Chelation therapy with EDTA and high-dose vitamin therapy both would be superior to placebo in post-MI patients. (
  • In a 2 x 2 factorial design, patients were randomized to receive either chelation or placebo infusions, and oral vitamins or placebo. (
  • A total of 1,708 patients were randomized, 839 to chelation and 869 to placebo, and 853 to high-dose vitamins and 855 to placebo. (
  • Diabetic patients in particular seemed to derive a higher benefit with chelation therapy as compared with placebo (HR 0.61, 95% CI 0.45-0.83, p = 0.002). (
  • EDTA Chelation also benefits patients with angina, gangrene or neuropathy. (
  • Dr. Lamas will also talk about the benefits and risks of chelation therapy, interpret its effects on patients with diabetes, and provide insights for future chelation therapy research. (
  • The goal of therapy in patients with iron overload disorders is to remove the iron before it can produce irreversible parenchymal damage. (
  • The randomized double blind study compared patients who were treated with Chelation to those without Chelation. (
  • He opened Immunity Therapy Center in 2007 with the goal of providing the highest quality medical care for more than 5,000 patients. (
  • Rectal suppository EDTA broadens the field of EDTA chelation patients in every way. (
  • Combined therapy in which deferiprone is given daily and DFO on a few days each week has been found to be effective in patients for whom either drug alone, for whatever reason, is inadequate. (
  • Some patients experience relief from their migraines directly after receiving chelation therapy. (
  • In Jamaica, the greatest mortality occurs between 6 and 12 months old when 10% of patients die despite considerable experience in the diagnosis and therapy of the condition and absence of malaria. (
  • RÉSUMÉ Des méthodes non-invasives de haute précision sont nécessaires pour l'évaluation de la concentration en fer dans les organes des patients atteints de thalassémie. (
  • Most triazole agents are not effective in vivo ( 10 ), except for posaconazole, which shows some efficacy both experimentally and in patients as second-line therapy ( 11 - 13 ). (
  • Chelation therapy of patients with symptoms attributed to amalgam fillings. (
  • Chelation therapy is considered a type of alternative or holistic medicine that reduces or removes a variety of wastes from the body. (
  • Chelation actually defines a process by which minerals such as iron or lead adheres to or combines with red blood cells, removing excess accumulation of such minerals or toxic wastes in the body . (
  • Proponents of chelation treatment believe that increased blood flow and circulation restores oxygen and nutrients to vital organs throughout the body, and may even be used as a cancer preventative. (
  • Biologically Based Therapies Complementary or alternative medicine can be classified into five major categories of practice: Whole medical systems Mind-body techniques Biologically based practices Manipulative and body-based. (
  • Practitioners of chelation therapy believe that many disorders are caused by having too much of a metal in the body even when people were not exposed to the metal and blood tests do not show high levels of the metal. (
  • Use of chelation therapy may also cause harm by altering other body chemistries, including causing low blood sugar. (
  • The chelate-therapy helps the body to regenerate itself. (
  • Chelation therapy can improve health by removing excessive levels of toxic minerals in the body. (
  • Chelation Therapy is a process that cleans the cardiovascular system by helping the body cleanse the arteries as well as detoxify the liver and kidneys. (
  • If you are concerned about heavy metal buildup in the body or are suffering from arthritis, chelation therapy may be right for you. (
  • IV therapy ensures increased bioavailability, so a greater proportion of the administered substance reaches its target and is available for use by the body. (
  • EDTA chelation has proven itself to be an effective method to detoxify your body from lead poisoning and other metal toxicities found in your body. (
  • Chelation improves cardiovascular function and improves blood flow to all the organs of the body including the heart. (
  • People who are under chelation therapy are primarily tested for kidney function because that is necessary for the body to tolerate such IV treatment. (
  • With any therapy (traditional, allopathic or alternative methods) it is very important to carry out the required procedures under properly qualified practitioners and with good medical supervision and Chelation Therapy is no different. (
  • Both allopathic and alternative medicine practitioners and public health specialists need to be aware of the potential for contamination of and side effects from alternative pharmacologic and herbal therapies. (
  • Several studies have shown that Chelation therapy can help arthritis sufferers experience significant improvement in their symptoms. (
  • EDTA Chelation is an effective treatment for these symptoms by removing the plaque that accumulates in blood vessels. (
  • In response to increasing use of chelation therapy as alternative medicine and in circumstances in which the therapy should not be used in conventional medicine, various health organizations have confirmed that medical evidence does not support the effectiveness of chelation therapy for any purpose other than the treatment of heavy metal poisoning. (
  • We explain how chelation therapy works before diving into some of its less conventional uses to see whether it's actually effective. (
  • Overview of Integrative, Complementary, and Alternative Medicine Integrative medicine and health (IMH) and complementary and alternative medicine (CAM) include a variety of healing approaches and therapies that historically have not been included in conventional. (
  • A total of 40 chelation or matching placebo infusions were administered (at least 3 hours for each infusion). (
  • We hope to improve pain, mobility, and overall health through a combination of Chelation therapy and other IV infusions. (
  • Disposable prefilled infusions designed to give 24 or 48 hours continuous therapy increase compliance but also costs. (
  • Chelation therapy can be traced back to the early 1930s, when Ferdinand Münz, a German chemist working for I.G. Farben, first synthesized ethylenediaminetetraacetic acid (EDTA). (
  • Chelation and therapy utilizing various forms of EDTA (also known as ethylenediaminetetraacetic acid), has been used for nearly four decades in the United States alone, approved by the U.S. Food and Drug Administration. (
  • Aetna considers the use of chelation therapy experimental and investigational in the prevention and treatment of cancer, cardiovascular disease (e.g., atherosclerotic cardiovascular disease , coronary artery disease, individuals who had a myocardial infarction), neurodegenerative diseases (e.g. (
  • therapy for by-pass surgery in atherosclerotic cardiovascular disease for more than four decades. (
  • Chelation therapy is believed to help prevent or relieve a variety of illnesses, including hardening of the arteries, atherosclerotic disease, age related decline and degenerative disease processes. (
  • Chelation may help restore function to the lining of the arteries that carry the oxygen and nutrition throughout our bodies. (
  • A naturopathic physician who is duly qualified and licensed by the College of Naturopathic Physicians of British Columbia may be certified to practice IV therapy or IV & chelation therapies provided they have successfully completed all of the requirements for the corresponding certification. (
  • Registrants who hold IV & Chelation Therapies Certification may restore their IV Therapy Certification by completing the following application form if they no longer wish to provide chelation therapies as part of their practice. (
  • This is a positive development for all who practice Chelation therapy. (
  • The study shows that Chelation is safe if properly administered and those who practice Chelation can now show that there is scientific support for using Chelation. (
  • Your provider may also suggest a related, complementary IV therapy, such as lipotropic therapy. (
  • For one, we can also offer you complementary therapies, like lipotropic therapy. (
  • When end-stage liver disease progresses despite iron-reduction therapy, orthotopic liver transplantation is the only therapeutic option. (
  • Chelation Therapy or Liver Transplantation? (
  • Chelation therapy itself began during World War II when chemists at the University of Oxford searched for an antidote for lewisite, an arsenic-based chemical weapon. (
  • Peggy Adkins discussed her personal experiences with chelation therapy for arsenic. (
  • One of the side benefits of EDTA Chelation therapy has been a dramatic improvement of arteriosclerosis condition. (
  • However, studies suggest that these benefits of chelation therapy are insignificant or nonexistent. (
  • Despite the benefits, EDTA chelation does have its detractors. (
  • link to What Are the Benefits of Chelation Therapy? (
  • What Are the Benefits of Chelation Therapy? (
  • What are the benefits of chelation therapy treatment, and are these really proven effective in treating various sicknesses? (
  • We'll also explain Palm Coast chelation therapy, including the risks, benefits, and procedure in detail. (
  • Some research supports that chelation therapy can help heart and blood vessels, improve kidney function, increase brain blood flow, and more, but there is still research to be done on these benefits. (
  • You could be an ideal candidate for the therapy if its benefits outweigh the risks. (
  • For example, a large-scale clinical study involving participants who'd previously had a heart attack didn't show enough evidence to support the routine use of chelation therapy for heart disease. (
  • Furthermore, Na 2 EDTA contains a warning stating, 'The use of this drug in any particular patient is recommended only when the severity of the clinical condition justifies the aggressive measures associated with this type of therapy. (
  • TACT was a 7 year placebo controlled clinical trial funded by the NIH and carried out by university cardiologists and Chelation Doctors from the USA and Canada. (
  • This report describes three deaths associated with chelation-therapy--related hypocalcemia that resulted in cardiac arrest. (
  • In 2005 , the Texas Department of Health childhood lead poisoning surveillance program reported a death attributable to chelation-associated hypocalcemia to CDC. (
  • Adverse events were mostly similar, although hypocalcemia (6.2% vs. 3.5%, p = 0.008) was higher in the chelation therapy arm. (
  • The use of chelation therapy for Alzheimer's disease is based on the belief that it's caused by a buildup of aluminum in the brain from aluminum pots and pans, water, food, and deodorant. (
  • Chelation therapy is believed to reduce or destroy free radicals caused by environmental pollution or chemicals that cause damage to cells, tissues and organs. (
  • In :Bucker CD, Gale RP, Lucarelli G. Advances and controversies in thalassemia therapy - bone marrow transplantation and other approaches. (
  • Whether you're run down and need a boost, suffering from chronic fatigue or Lyme disease, or undergoing cancer treatment, IV Therapy is a powerful, proven tool in improving health. (
  • It was inevitable, given that more and more parents of autistics, desperate to do anything to help their children, are opting for this unproven and ineffective therapy. (
  • Do you still suggest taking replacement minerals when taking oral chelation? (
  • Originally designed for replacing essential minerals in between chelation, this IV is now highly recommended for cardiovascular support. (
  • The Myer's cocktail IV is a popular option of chelation therapy that is a combination of high dose magnesium, trace minerals and vitamin C. (
  • Chelation removes toxic metal ions, and can be used to treat some cases of cancer, as well as heart disease. (